Tackling “the Biggest Question That Everyone Is Asking” in Breast Cancer Care

About this episode

The episode discusses the current approaches to treating ESR1-mutated advanced breast cancer and the potential use of SERDs in various patient scenarios.

How are oncologists currently approaching the care of patients with ESR1-mutated advanced breast cancer in practice? Erin Frances Cobain, MD, associate professor at the University of Michigan Rogel Cancer Center in Ann Arbor, speaks with Wassim Mchayleh, MD, MBA, the clinical program director of the breast cancer program at AdventHealth Cancer Institute and associate professor of medicine at the University of Central Florida in Orlando, about how to best use oral selective estrogen receptor degraders. “And the big question is ‘Can we use SERDs in combination, or are SERDs effective in patients without an ESR1 mutation?’ Can we go outside the current approved guidelines? And I think that’s the biggest question that everyone is asking today,” notes Dr. Mchayleh.

People in this episode

Host: Erin Frances Cobain, MD

Guest: Wassim Mchayleh, MD, MBA

Topics covered

• breast cancer
• ESR1 mutation
• oncology
• SERDs
• advanced breast cancer
• patient care

Keywords

• breast cancer care
• ESR1 mutation
• oral selective estrogen receptor degraders
• oncologists
• advanced breast cancer

Mentioned in this episode

Organizations: University of Michigan Rogel Cancer Center, AdventHealth Cancer Institute, University of Central Florida

More episodes of Oncology News Central Peer-Spectives

• “Not a Straightforward Decision”: What to Do While Waiting on a Practice Change in Breast Cancer Care · April 29, 2026 · 11 min
• New Targeted Therapies Make Breast Cancer Treatment Decisions “a Bit of a Moving Target” · April 21, 2026 · 9 min
• Advances in ESR1-Mutated Breast Cancer Care Lead to “Complex Situation” in Clinic · April 17, 2026 · 12 min
• Shared Decision Making and Toxicity Management in EGFR- Mutated Advanced NSCLC · December 18, 2025 · 12 min
• “Where the Real Answer Lies”: How CNS Disease Influences EGFR-Mutated NSCLC Treatment Decisions · December 18, 2025 · 15 min
• “Is the Juice Worth the Squeeze?”: Treatment Intensification for Advanced EGFRm NSCLC · December 16, 2025 · 13 min